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METHODOLOGY AND GUIDELINE
DEVELOPMENT ISSUES
MGAI
IMPROVING CLINICAL OUTCOMES
BY INTEGRATING A NORMALIZED,
STANDARDIZED, COMPARATIVE
DATABASE INTO THE PROCESS OF
CLINICAL QUALITY IMPROVEMENT
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We demonstrate the use of a novel database approach to
drive the process of quality improvement in patients ad-
mitted under DRG 209, major joint and limb reattach-
ment procedures of lower extremity.
METHODS: (1) Using standardized mapping criteria con-
tained in the Perspective Comparative Databaserm (PCD)
provided by Premier, Inc., a peer group of 12 similar institu-
tions were selected. (2) PCD provided standardized cost and
usage comparative data, including resource consumption by
ICD-9 at the departmental charge code level, attending phy-
sician mix by specialty, average charges, costs, length of stay
age and gender ratios by ICD-9 code (all payer data includ-
ing Medicare), readmission to DRG 209 and to any DRG at
30, 60, and 90 days, primary admitting and discharge mix.
(3) A multidisciplinary CQI team was asked to focus im-
provement efforts on the departmental level costs and use
the benchmark peer groups as a comparison.
RESULTS: Analysis of the ICD-9 group that impacted
DRG 209 that included total knee replacements (lCD-9
81.54) and total hip replacement (ICD-9 81.51), which
represented 80% of all evaluated patients. 70% of the pa-
tients were female, 70% were Medicare and 70% were
between the ages of 60 and 89. The PCD comparative re-
ports showed that nursing, physician, and resource utili-
zation had dollar variances from 23% to 82%. This en-
ables the team to analyze whether the higher costs were
due to over-utilization of resources (test, doses, supplies,
critical care nursing days, etc.) or to resources that were
properly used but too expensive.
CONCLUSION: CQI processes driven by data produce
rapid targeted improvement in clinical outcomes. This is
only possible if the database provided is accepted by all
participants.
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The recent Sixth Report of the Joint National Committee
on the Prevention, Detection, Evaluation, and Treatment
Abstracts
of High Blood Pressure reported that barely half of pa-
tients treated for hypertension achieve control of blood
pressure (BP).
OBJECTIVE: To estimate the clinical and economic ben-
efits of disease management programs aimed at achieving
BP goals in treated hypertensives.
METHODS: We developed an economic model of car-
diovascular disease (CVD) and its relationship to dias-
tolic blood pressure (DBP) and antihypertensive treat-
ment. This model forecasts CVD incidence and direct
medical-care costs for specified populations, such as the
membership of a managed-care plan, and simulates the
effect of programs to improve BP control. CVD risk was
estimated using new equations developed for this purpose
from the Framingham Heart Study. Other principal data
sources included major national health surveys and
healthcare costs databases.
RESULTS: We estimate that in an average healthcare
plan, 22% of members aged 40-79 years receive anti-
hypertensive therapy, and at routine follow-up 15% of
the latter will be found to have uncontrolled DBP (~90
mmHg). For every 1,000 such patients, further interven-
tion to achieve BP control is expected to prevent 39 CVD
events and save $515,000 in CVD treatment costs over
five years. If intervention is limited to those with prior
history of CVD it will prevent 54 events and save
$834,000 per 1,000 patients. Further limitation of inter-
vention to those ~60 years of age increases these benefits
to 67 events and $1,014,000 per 1,000.
CONCLUSION: Disease management programs that tar-
get treated but uncontrolled hypertensives can be ex-
pected to yield substantial economic benefits in addition
to preventing cardiovascular morbidity and mortality.
A NEW PARADIGM FOR ASSESSING
HEALTH-RELATED QUALITY OF LIFE:
A SOCIAL-CLINICAL MODEL
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The objectives of this study were to confirm the factorial
validity of a health-related quality of life (HRQL) instru-
ment (Functional Assessment of Cancer Therapy), estab-
lish equivalence of the HRQL instrument across three ra-
cial/ethnic groups, and examine the impact of social and
clinical factors on HRQL in diverse cancer patients.
METHODS: Data used in this study were supplied by
three Eastern Cooperative Oncology Group (ECOG) data
collection sites. A total of 911 patients with complete data
were included in the cross-sectional analyses. This study
includes seven exogenous (observed) variables (age, socio-
economic status, living arrangement, gender, race/ethnic-
ity, disease stage, and performance status) and one exoge-
nous latent variable (spiritual beliefs). The multivariate
analyses include exploratory factor analysis, confirmatory
factor analysis, and structural equation modeling.
RESULTS: The construct validity of a commonly used
